BofA raised the firm’s price target on Hutchmed (HCM) to $27 from $26 and keeps a Buy rating on the shares. While noting it sees “some regulatory headwinds potentially ahead,” the firm keeps a Buy rating on the shares and cites higher revenue expectations for key assets after “strong performance in 2024” for its revised price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCM:
- Hutchmed announces NMPA approval for Orpathys supplemental new drug application
- Hutchmed price target lowered to $26 from $30 at BofA
- Morning Movers: Neumora Therapeutics plummets after KOASTAL-1 misses endpoint
- Hutchmed announces NDA acceptance in China, payment from AstraZeneca
- Hutchmed divests 45% interest in Shanghai Hutchison for $608M